Jorge Reis-Filho, AstraZeneca-澳门葡京网赌游戏

As the VP of Cancer Biomarker Development, I lead a dedicated team focused on developing and validating mechanistically-informed yet clinically-deployable biomarkers for patient selection and therapeutic response prediction. Our aim is to identify and treat patients earlier, minimise unwanted effects from treatment, and help design innovative clinical trials based on rigorous science.

With a background in molecular pathology, bioinformatics, functional genomics and artificial intelligence, I have pioneered innovative methods to decipher cancer genomics, intra-tumour genetic heterogeneity and DNA repair defects.

In my previous role as the Chief of Experimental Pathology at Memorial Sloan Kettering Cancer Center, I leveraged my expertise to bridge academic medical research with biotechnology and pharmaceutical industries. I have served on numerous scientific advisory boards, on the Board of Directors for Grupo Oncoclínicas, and as a consultant for multiple biotech companies and Goldman Sachs Merchant Banking. In these roles, I provided scientific, clinical, and technical advice in the support of healthcare, healthtech, biotech, and big data strategies, seeking to revolutionise cancer diagnosis and treatment through omics and computational pathology solutions. I have also had senior editorial roles in pathology, oncology and research journals, including The Journal of the National Cancer Institute, The Journal of Pathology, and npj Breast Cancer.

I have a passion about nurturing the next generation of scientists and promoting diversity within the scientific community. Throughout my career, I have collaborated with talented individuals from diverse backgrounds, united by a shared commitment to harnessing science for positive change.

My work integrates the fields of molecular pathology, bioinformatics, functional genomics and artificial intelligence to develop optimal biomarkers to ensure that patients receive the right treatment at the optimal point in their therapeutic journey.

Jorge Reis-Filho Vice President, Cancer Biomarker Development, AstraZeneca

2024

William Gerald Award, Department of Pathology, Memorial Sloan Kettering Cancer Center

2023

The Goudie Medal, The Pathological Society of Great Britain and Ireland

2010

Ramzi Cotran Young Investigator Award, United States and Canadian Academy of Pathology

2012 – 2023

Chief of Experimental Pathology, Memorial Sloane Kettering Cancer Center, New York, USA

2016 – 2023

Consultant and/or scientific advisory board member at Goldman Sachs Merchant Banking, Bain Capital, Paige.ai, Repare Therapeutics, and Saga Diagnostics, among others

2010 – 2012

Professor and Chair of Molecular Pathology, The Institute of Cancer Research, London, UK

Career highlights

2005

Development of the first arrayCGH platform that could utilise DNA from FFPE samples

2017

Development of first single-cell DNA-sequencing method for the analysis of cells extracted from FFPE samples

2019

Development of first high intensity ctDNA assay

2021

First FDA cleared computational pathology solution for the detection of prostate cancers in biopsies

Featured publications

Chromothripsis-mediated small cell lung carcinoma

Regression-based Deep-Learning predicts molecular biomarkers from pathology slides

Cancer-Causative Mutations Occurring in Early Embryogenesis

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors

Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples

Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands

Triple-negative breast cancer

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

Resistance to therapy caused by intragenic deletion in BRCA2

Veeva ID: Z4-70120
Date of preparation: November 2024